Alkermes plc Launches Corporate Operations in Ireland
- Company Establishes Headquarters in Dublin -
- Company Announces Manufacturing Deal Expected to Generate Escalating Revenues Reaching $15 Million to $20 Million Annually -
DUBLIN, Sep 19, 2011 (BUSINESS WIRE) -- Alkermes plc (NASDAQ: ALKS) today announced the establishment of its corporate operations in Ireland, with new headquarters located in Dublin. The company, including its headquarters and operations in Athlone, County Westmeath, has more than 450 employees based in Ireland and more than 1,200 employees worldwide.
Alkermes plc was created following the merger of Alkermes, Inc. with Elan Drug Technologies (EDT), the profitable, world-class drug formulation and manufacturing business unit that was formerly a part of Elan Corporation, plc.
Marking its first day of operations in Ireland, Alkermes has announced a multiyear, multimillion dollar manufacturing agreement with one of the world's top ten pharmaceutical companies. Under the terms of the agreement, Alkermes will manufacture the company's finished pharmaceutical product, which will be produced at Alkermes' Athlone, Ireland facility. Alkermes expects this agreement to generate $15 million to $20 million in annual manufacturing revenues by 2016. The Athlone facility is one of three major manufacturing plants owned by Alkermes plc at which the company produces proprietary, partnered and contract-manufactured drug products.
Welcoming today's announcement, Mr. John Perry TD, Minister of State for Small Business said, "Alkermes plc's decision to establish its headquarters in Ireland is further demonstration of this country's continued ability to attract companies, like Alkermes, in growth industries, to set up operations here. Today's announcement showcases that Ireland is very much open for business and is an excellent location to host operations of multinational companies. The additional announcement of a new contract for the Athlone facility is an indication of its track record for successful innovation and high-quality manufacturing."
"We are a strong, global company with a diversified product portfolio, and we look forward to accelerating our growth to create value in our business and for the patients we serve," said Richard Pops, Chief Executive Officer of Alkermes. "Alkermes is excited to have our operations based in Ireland, which we view as a gateway to the European Union and global pharmaceutical market."
| "Research Prioritisation - Consequences for the Life Sciences Industry"
Also featuring a showcase of the Trinity Biomedical Sciences Institute’s research capability and facilities
This event is FREE to attend but registration is required at www.biotechnologyireland.com
When: May 31st 2012 at 1.15pm Where: The Trinity Biomedical Sciences Institute, Pearse Street, Dublin 2 Map >> Rationale for this event: Significant investment has taken place in science, technology and innovation in recent years with emphasis on building up research capacity within higher education and research institutes. The investment is driven by the desire for Ireland to be a competitive, 21st century, knowledge-based economy. The Research Prioritisation Steering Group has recently recommended to Government areas for future R&D focus ( Summary >> ).
This timely and relevant event will provide an overview of the recommendations and will discuss how Ireland can leverage its capability to deliver economic returns in the form of jobs and growth. The event will also feature a showcase of the Trinity Biomedical Sciences Institute’s research capability which reflects the degree of research prioritisation that has taken place in Trinity College Dublin over recent years. Speakers and panellists: Maurice Roche, Delta Partners, and member of the Research Prioritisation Project Steering Group will outline the purpose and outcome of the Research Prioritisation exercise. This will be followed by a discussion with a panel which includes Enda Connolly, CEO of the Health Research Board; Matt Moran, Director of PharmaChemical Ireland; and Dr Keith O’Neill, Director, Life Sciences & Food Commercialisation, Enterprise Ireland. The panel will offer views on the consequences of this report for the life sciences sector. Who should attend? Representatives of companies from start-up to multinational, entrepreneurs , innovators, founders, CEOs, scientists, engineers, clinicians, technology and life sciences professionals, technology transfer and commercialisation professionals, service providers, business development and senior management in the technology, research, venture capital, and life sciences sectors. Programme: Download the programme and speaker list here>> Agenda: 1.15 pm Registration and Networking Lunch (Soup/Sandwiches/Tea/Coffee) 2.00 pm A showcase of the Trinity Biomedical Sciences Institute’s research capability.
The Trinity Biomedical Sciences Institute is a state-of-the-art research facility built around the areas of immunology, cancer and medical devices and links directly to both medical education and industrial collaboration. This session will provide a whistle-stop view of the research and development expertise that is accessible at the Trinity Biomedical Sciences Institute. Presenters include Prof. Luke O’Neill (Inflammation), Prof. Kingston Mills (Immune Regulation), Dr Kenneth Mok (Biochemistry), Prof. Marek Radomski (Pharmaceutical), Prof. Padraig Fallon (Inflammation & Immunity), Prof. Mathias Senge (Organic Chemistry & Photomedicine), Prof Thorri Gunnlaugsson (Supramolecular & Medicinal Chemistry) , Prof. Richard Reilly (Neural Engineering) and Prof Cliona O'Farrelly (Comparative Immunology). 3.00 pm Open Mike Presentations (3-minute presentations of relevance to the sector) 3.15 pm Discussion of the Research Prioritisation exercise and the consequences of its recommendations for the Life Sciences Industry 4.30 pm Networking Reception.
Tours will be available of the 3000 m2 Industry Academic Collaboration space, available to lease by companies who wish to partner with the University in developing intellectual property through collaborative research, or who would benefit from access to research teams and / or use of R&D facilities on-campus.
This event is FREE to attend but registration is required at www.biotechnologyireland.com
OPEN MIKE SLOTS: Up to five individuals can get 3 minutes each to introduce themselves or their organisation to their BioConnect Ireland colleagues. If you are interested in availing of an Open Mike slot, please register your interest using the OPEN MIKE registration form at: www.biotechnologyireland.com BioConnect Ireland is sponsored by:
Enterprise Ireland, RFT Group, Seroba Kernel This event is in association with Trinity College Dublin
| |
Minister Bruton signs Memorandum of Understanding on Science and Technology with Chinese Government
27th March 2012
Richard Bruton T.D, Minister for Jobs Enterprise and Innovation today (Tuesday) in Beijing signed a memorandum of understanding on Ireland-China Science and Innovation Cooperation with Mr. Wan Gang, Minister of Science and Technology, during Minister Bruton’s 7-day trade and investment mission to China.
The memorandum sets out the objectives and modes of cooperation on science and innovation between the two countries. Cooperative activities envisaged include exchange of scientific and technological information and data, exchange of scientists, researchers, technicians and trainees for visits, study tours and advanced studies, organisation of bilateral scientific and technical meetings and joint research on projects of mutual interest.
On the basis of this Memorandum of Understanding, both Departments will finalise arrangements to begin cooperative activities this year.
Minister Bruton stated:
“Through the Action Plan for Jobs, the Government is committed to delivering a series of measures to build on our base of scientific research to help create economic growth and jobs. Increasingly our research is industry-led, and is aimed at commercial outcomes and job-creation, but we must do more.
“Ireland and China have participated in a number of research partnerships over the past decade but through the signature of this Memorandum of Understanding we look forward to more and more linkages between Irish research groups and innovative companies with counterparts in China.”
“By combining expertise in specific areas such as life sciences, groups from both countries can find solutions to problems or to discover new techniques to improve our lives and help create jobs”.
Alkermes Plc. Announces new Global Corporate Headquarters in Dublin
29/03/12
Dublin Headquarters are Central to Alkermes’ European and Global Growth Strategy
Ireland has established a solid track record as the ideal location for many of the world’s leading pharmaceutical businesses. We see our Dublin base as important to the evolution of our business, both in our European markets and globally. We look forward to building a substantial biopharmaceutical business, based in Ireland, with the goal of bringing innovative medicines to the patients we serve.
Richard Pops, Chief Executive Officer of Alkermes plc.
Alkermes plc (NASDAQ: ALKS) today marked the official opening of its new global corporate headquarters in Ireland, located at Connaught House1 on Burlington Road in Dublin. Minister for Health, Dr. James Reilly TD, joined the Alkermes plc leadership team at a reception to commemorate the opening of the company’s new corporate headquarters.
The company employs more than 400 people in Ireland at its manufacturing and drug development facility in Athlone, Co. Westmeath and at its global headquarters operation in Dublin, with more than 1,200 employees worldwide.
Commenting at today’s event, Richard Pops, Chief Executive Officer of Alkermes plc, said:
“Ireland has established a solid track record as the ideal location for many of the world’s leading pharmaceutical businesses. We see our Dublin base as important to the evolution of our business, both in our European markets and globally. We look forward to building a substantial biopharmaceutical business, based in Ireland, with the goal of bringing innovative medicines to the patients we serve.”
Last September, the company announced a multiyear, multimillion-dollar manufacturing agreement for its Athlone plant with one of the world’s top ten pharmaceutical companies.
Speaking at the opening ceremony, Minister James Reilly said:
“I am delighted to welcome Alkermes to Ireland and wish the company every success in its continued development of innovative new products. I have no doubt that Alkermes has an important role to play both in the future success of our economy and in improving outcomes for patients.”
Welcoming the official opening of Alkermes’ new global corporate headquarters in Dublin, Barry O’Leary, Chief Executive Officer of IDA Ireland said:
“Ireland is a leading location for life sciences companies and home to 9 of the top 10 global pharmaceutical companies, with 7 of the top 10 pharmaceutical blockbuster products manufactured here. The continued growth and success of Alkermes further adds to Ireland’s reputation as a hub for the pharmaceutical sector. On behalf of IDA Ireland, I wish Alkermes ongoing success with this operation and offer the continued support of IDA Ireland.”
Alkermes plc was formed following the merger of Alkermes, Inc. and Elan Drug Technologies (EDT), in September 2011. The company established its global headquarters in Ireland following the completion of the merger.
MORE THAN 280 jobs were announced by three international companies in Tralee, Co Kerry, yesterday as part of an initiative to locate test centres in biomedicine, drug testing and pharmaceutical research in a new campus.
The planned jobs are in research and development (RD) and are to come on stream over the next 15 months. They will be based temporarily in an existing building in the town and recruitment will begin in May.
Over the next four years up to 50 small-to-medium-sized businesses will form part of the €4.7 billion Global Pharmaceutical Centre of Excellence ( GPCE) project, employing up to 4,500, presentations at the Shannon Development Headquarters in Tralee and the county council chambers heard.
The 282 jobs will be created by the International Prevention Research Institute, Global Research Services (GRS) and Optivia Biotechnology.
Prof Peter Boyle, head of the institute, a non-profit organisation advising several governments on public health, said the initiative by the GPCE was necessary for the development of medicine.
“This could be a very important centre for the whole of Europe in five years,” Prof Boyle said.Dr Peter Milner of Optivia Biotechnology, based in Silicon Valley in the US, said he envisaged 500 studies with an investment of $5 million (€3.6 million) in the first year alone. His company’s focus is in pre-clinical trials.
Optivia would need up to 30,000sq ft of laboratory space.
The new jobs will initially be at the Centrepoint building in Tralee. But a planning application is to be submitted in May for a 32-acre site alongside the Institute of Technology Tralee, according to Rory Doyle, chief executive of the proposed centre, and a senior executive with Pharmadel, the Cork-based generic drug firm.
The plans for a four-storey building with floor space of 27½ acres overlooking Tralee Bay at the Kerry Technology Park were unveiled. It will comprise laboratories and an auditorium larger than that of the new convention centre in Dublin, architects said.
Significant State investment is required to ensure the project proceeds, its promoters said. Former minister for finance Alan Dukes, a board member of GPCE, said yesterday was the first “concrete manifestation” of the project, which was receiving great help from the IDA and Shannon Development.
-------------------------------------------------------------------------------------------
Irish Business Success Stories - new video features Radisens and Aerogen
http://www.enterprise-ireland.com
Thanks to our sponsors:
